Evidence map›Paper›PMID 39847078›Full record

ArticleArchives of toxicology2025

A physiologically based pharmacokinetic (PBPK) model describing the kinetics of a commercial mixture α-, β-, and γ-hexabromocyclododecane exposure in mice.

Claude Emond, Michael J DeVito, Linda S Birnbaum

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Claude EmondBioSimulation Consulting Inc., Crabtree, QC, Canada. claude.emond@biosmc.com.ORCID 0000-0001-6593-964X
Michael J DeVitoCenter for Computational Toxicology and Exposure, Chemical Characterization and Exposure Division, U.S. Environmental Protection Agency, Research Triangle Park, NC, USA.
Linda S BirnbaumScientist Emeritus, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA.

Funding

Studies of the fate of environmental contaminants in humans and animalsZIABC011476 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI BIRNBAUM, LINDA · 2013 to 2019
$5.8M
NIH HHS HHSN261201800377PNIH HHS ZIA BC 011476
6 · The paper itself

Abstract

Hexabromocyclododecane (HBCD) is a brominated flame retardant, that is added, but not chemically bonded, to consumer products. HBCD is sold as a commercial-grade HBCD mixture containing three major stereoisomers: alpha (α), beta (β), and gamma (γ), with relative amounts of 12% for α-HBCD, 6% for β-HBCD, and 82% for γ-HBCD. HBCDs are widely measured in the environment and in biological matrices. The toxicological effects of its exposure in humans are not clearly understood. A recent reassessment pointed out potential thyroid disruption as a primary effect. This current work aims to update a physiologically based pharmacokinetic (PBPK) model for γ-HBCD in C57BL/6 mice and incorporate equations and codes for α-HBCD and β-HBCD isomers and simulate them as a mixture. Physiological parameters were taken from the literature, calculated based on the log K

Indexed as

Flame RetardantsHydrocarbons, BrominatedModels, BiologicalAnimalsMaleMiceMice, Inbred C57BLTissue DistributionFlame RetardantshexabromocyclododecaneHydrocarbons, BrominatedHBCDHBCDsMixturePBPKPharmacokineticsToxicityα-HBCDβ-HBCD

Identifiers

PMID39847078

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.